Cessation of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.

Melissa E MiddeldorpAashray GuptaAdrian ElliottKadhim KadhimAnand ThiyagarajahCeline GallagherJeroen M L HendriksDominik LinzMehrdad EmamiRajiv MahajanDennis LauPrashanthan Sanders

Published in: Heart (British Cardiac Society) (2020)

In this 'real world' cohort, NOAC use is safe and well-tolerated when prescribed in an integrated care clinic. Whether apixaban is better tolerated compared with other NOACs warrants further study.

Keyphrases

oral anticoagulants
atrial fibrillation
healthcare
primary care
palliative care
venous thromboembolism
quality improvement